Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 29 of 29 publications.

DiBenedetti D, Neme D, Pan-Petesch B, Willemze A, Wynn T, Kragh N, Wilson A. Patient experience with efanesoctocog alfa for severe hemophilia A: results from the XTEND-1 phase 3 clinical study exit interviews. Clin Ther. 2024 Oct 15;S0149-291. doi: 10.1016/j.clinthera.2024.09.010

Meyers J, Hoog M, Mody R, Yu M, Davis K. The health care resource utilization and costs among patients with type 2 diabetes and either cardiovascular disease or cardiovascular risk factors an analysis of a US health insurance database. Clin Ther. 2021 Nov;43(11):1827-42. doi: 10.1016/j.clinthera.2021.09.003

van der Wall SJ, Lip GYH, Teutsch C, Kalejs O, Lyrer P, Hall C, Dubner SJ, Diener HC, Halperin JL, Ma CS, Rothman KJ, Zint K, Zhai D, Huisman MV, GLORIA-AF Investigators. Low bleeding and thromboembolic risk with continued dabigatran during cardiovascular interventions: the GLORIA-AF study. Eur J Intern Med. 2021 Sep;91:75-80. doi: 10.1016/j.ejim.2021.05.020

Ervin C, Joish VN, Evans E, DiBenedetti D, Reaney M, Preblick R, Castro R, Danne T, Buse JB, Lapuerta P. Insights into patients' experience with Type 1 diabetes: exit interviews from phase III studies of sotagliflozin. Clin Ther. 2019 Nov;41(11):2219-2230. doi: 10.1016/j.clinthera.2019.09.003

Meyers J, Sinha A, Samant S, Candrilli S. The economic burden of congenital cytomegalovirus disease in the first year of life: a retrospective analysis of health insurance claims data in the United States. Clin Ther. 2019 Jun;41(6):1040-1056. doi: 10.1016/j.clinthera.2019.04.022

Maiese EM, Ainsworth C, Le Moine JG, Ahdesmaki O, Bell J, Hawe E. In reply: Network meta-analyses are not about a single treatment but about sets of regimens. Clin Ther. 2019 Jan;41(1):188-90. doi: 10.1016/j.clinthera.2018.11.011

Maiese EM, Ainsworth C, Le Moine JG, Ahdesmaki O, Bell J, Hawe E. Comparative efficacy of treatments for previously treated multiple myeloma: a systematic literature review and network meta-analysis. Clin Ther. 2018 Mar;40(3):480-94. doi: 10.1016/j.clinthera.2018.01.014

Pontes C, Marsal JR, Elorza JM, Aragon M, Prieto-Alhambra D, Morros R. Analgesic use and risk for acute coronary events in patients with osteoarthritis: a population-based, nested case-control study. Clin Ther. 2018 Feb;40(2):270-83. doi: 10.1016/j.clinthera.2017.12.011

Anthony L, Ervin C, Lapuerta P, Kulke MH, Kunz P, Bergsland E, Horsch D, Metz DC, Pasieka J, Pavlakis N, Pavel M, Caplin M, Oberg K, Ramage J, Evans E, Yang QM, Jackson S, Arnold K, Law L, DiBenedetti DB. Understanding the patient experience with carcinoid syndrome: exit interviews from a randomized, placebo-controlled study of telotristat ethyl. Clin Ther. 2017 Nov 11;39(11):2158-68. doi: 10.1016/j.clinthera.2017.09.013

Earnshaw SR, McDade CL, Chu Y, Fleige LE, Sievenpiper JL. Cost-effectiveness of maintaining daily intake of oat β-glucan for coronary heart disease primary prevention. Clin Ther. 2017 Apr;39(4):804-818.e. doi: 10.1016/j.clinthera.2017.02.012

Donohue JF, Ganapathy V, Bollu V, Stensland MD, Nelson LM. Health status of patients with moderate to severe COPD after treatment with nebulized arformoterol tartrate or placebo for 1 year. Clin Ther. 2017 Jan;39(1):66-74. doi: 10.1016/j.clinthera.2016.11.021

Mladsi D, Ronquest N, Odom D, Miles L, Saag K. Cost-effectiveness of low-dose submicron diclofenac compared with generic diclofenac. Clin Ther. 2016 Nov;38(11):2418-29. doi: 10.1016/j.clinthera.2016.09.013

Bailey RA, Schwab P, Xu Y, Pasquale M, Renda A. Glycemic control outcomes after Canagliflozin initiation: observations in a Medicare and commercial managed care population in clinical practice. Clin Ther. 2016 Sep;38(9):2046-2057. doi: 10.1016/j.clinthera.2016.07.009

Graham CN, Maglinte GA, Schwartzberg LS, Price TJ, Knox HN, Hechmati G, Hjelmgren J, Barber B, Fakih MG. Economic analysis of panitumumab compared with cetuximab in patients with wild-type KRAS metastatic colorectal cancer that progressed after standard chemotherapy. Clin Ther. 2016 Jun;38(6):1376-91. doi: 10.1016/j.clinthera.2016.03.023

Kan H, Nagar S, Patel J, Wallace DJ, Molta C, Chang DJ. Longitudinal treatment patterns and associated outcomes in patients with newly diagnosed systemic lupus erythematosus. Clin Ther. 2016 Mar;38(3):610-24. doi: 10.1016/j.clinthera.2016.01.016

Barnes R, Earnshaw S, Herbrecht R, Morrissey O, Slavin M, Bow E, McDade C, Charbonneau C, Weinstein D, Kantecki M, Schlamm H, Maertens J. Economic comparison of an empirical versus diagnostic-driven strategy for treating invasive fungal disease in immunocompromised patients. Clin Ther. 2015 Jun 1;37(6):1317-28. doi: 10.1016/j.clinthera.2015.03.021

Graham JE, Rouse M, Twiss J, McKenna SP, Vidalis AA. Greek adaptation and validation of the Ankylosing Spondylitis Quality of Life (ASQoL) measure. Hippokratia. 2015;19(2):119-24.

Odom DM, Mladsi DM, Saag KG, Sherif BN, Miles L, Ronquest N, Wang J. Relationship between diclofenac dose and risk of gastrointestinal and cardiovascular events: meta-regression based on two systematic literature reviews. Clin Ther. 2014 Jun;36(6):906-17. doi: 10.1016/j.clinthera.2014.04.012.

Hagiwara M, Borker R, Oster G. Economic burden of adverse events in patients with metastatic renal cell carcinoma. Clin Ther. 2013 Dec;35(12):1955-1963. doi: 10.1016/j.clinthera.2013.10.010

Coon CD, McLeod LD. Patient-reported outcomes: current perspectives and future directions. Clin Ther. 2013 Apr 1;35(4):399-401.

Earnshaw SR, McDade C, Chapman AM, Jackson D, Schwamm L. Economic impact of using additional diagnostic tests to better select patients with stroke for intravenous thrombolysis in the United Kingdom. Clin Ther. 2012 Jul 1;34(7):1544-58.

Wolowacz SE, Roskell NS, Maciver F, Beard SM, Robinson PA, Plumb JM, Dolan G, Brenkel IJ. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery. Clin Ther. 2009 Jan 1;31(1):194-212.

Meltzer EO, Stahlman JE, Leflein J, Meltzer S, Lim J, Dalal AA, Prillaman BA, Philpot EE. Preferences of adult patients with allergic rhinitis for the sensory attributes of fluticasone furoate versus fluticasone propionate nasal sprays: a randomized, multicenter, double-blind, single-dose, crossover study. Clin Ther. 2008 Feb;30(2):271-9. doi: 10.1016/j.clinthera.2008.02.005

Earnshaw SR, Moride Y, Rochon S. Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada. Clin Ther. 2007 Sep 1;29(9):2096-106.

Sanchez-Matienzo D, Arana A, Castellsague J, Perez-Gutthann S. Hepatic disorders in patients treated with COX-2 selective inhibitors or nonselective NSAIDs: a case/noncase analysis of spontaneous reports. Clin Ther. 2006 Aug 1;28(8):1123-32.

Sanchez-Matienzo D, Arana A, Castellsague J, Perez-Gutthann S. Hepatic disorders in users of NSAIDs, including COX-2 selective inhibitors. A case/non-case analysis of spontaneous reports. Clin Ther. 2006;28(8):1123-32.

Sapienza S, Sacco P, Floyd K, DiCesare J, Doan Q. Results of a pilot pharmacotherapy quality improvement program using fixed-dose, combination amlodipine/benazepril antihypertensive therapy in a long-term care setting. Clin Ther. 2003 Jun;25(6):1872-87.

Caro JJ, Klittich WS, Raggio G, Kavanagh PL, O'Brien JA, Shomphe LA, Flegel KM, Copley-Merriman C, Sigler C. Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of type 2 diabetes. Clin Ther. 2000 Jan;22(1):116-27.

Khalil S, Rodarte A, Weldon BC, Weinstein M, Grunwald Z, Ginsberg B, Kaye R, Otto A, Wheeler M, Lawhorn CD, Prillaman BA, Creed M. Intravenous ondansetron in established postoperative emesis in children. S3A-381 study group. Anesthesiology. 1996 Aug;85(2):270-6. doi: 10.1097/00000542-199608000-00007